| 1 |
35126712 | Harmine reinforces the effects of regorafenib on suppressing cell proliferation and inducing apoptosis in liver cancer cells. | 2022 Mar |
6 |
| 2 |
35244188 | DYRK1A suppression attenuates HIF‑1α accumulation and enhances the anti‑liver cancer effects of regorafenib and sorafenib under hypoxic conditions. | 2022 Apr |
1 |
| 3 |
35502476 | Regorafenib induces the apoptosis of gastrointestinal cancer-associated fibroblasts by inhibiting AKT phosphorylation. | 2022 May 2 |
3 |
| 4 |
34596810 | Catalpol synergistically potentiates the anti-tumour effects of regorafenib against hepatocellular carcinoma via dual inhibition of PI3K/Akt/mTOR/NF-κB and VEGF/VEGFR2 signaling pathways. | 2021 Nov |
3 |
| 5 |
32457362 | Regorafenib is effective against neuroblastoma in vitro and in vivo and inhibits the RAS/MAPK, PI3K/Akt/mTOR and Fos/Jun pathways. | 2020 Aug |
2 |
| 6 |
30929918 | Suppression of LSD1 enhances the cytotoxic and apoptotic effects of regorafenib in hepatocellular carcinoma cells. | 2019 May 14 |
1 |
| 7 |
31163381 | Apoptosis induction and AKT/NF-κB inactivation are associated with regroafenib-inhibited tumor progression in non-small cell lung cancer in vitro and in vivo. | 2019 Aug |
2 |
| 8 |
31238539 | Protein Kinase B and Extracellular Signal-Regulated Kinase Inactivation is Associated with Regorafenib-Induced Inhibition of Osteosarcoma Progression In Vitro and In Vivo. | 2019 Jun 24 |
2 |
| 9 |
31501414 | A positive feedback loop of β-catenin/CCR2 axis promotes regorafenib resistance in colorectal cancer. | 2019 Sep 9 |
1 |
| 10 |
29359239 | The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma. | 2018 May |
1 |
| 11 |
29609689 | Regorafenib delays the proliferation of hepatocellular carcinoma by inducing autophagy. | 2018 Apr 2 |
1 |
| 12 |
29783729 | Chlorogenic Acid Improves the Regorafenib Effects in Human Hepatocellular Carcinoma Cells. | 2018 May 19 |
2 |
| 13 |
28000898 | Regorafenib induces extrinsic and intrinsic apoptosis through inhibition of ERK/NF-κB activation in hepatocellular carcinoma cells. | 2017 Feb |
1 |
| 14 |
28166200 | Upregulation of MARCKS in kidney cancer and its potential as a therapeutic target. | 2017 Jun 22 |
1 |
| 15 |
28978118 | Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer. | 2017 Sep 15 |
1 |
| 16 |
26419617 | Involvement of Notch-1 in Resistance to Regorafenib in Colon Cancer Cells. | 2016 May |
1 |
| 17 |
25838391 | Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. | 2015 Jul 1 |
1 |
| 18 |
25132955 | Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitors. | 2014 |
1 |
| 19 |
23877009 | Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells. | 2013 Oct |
1 |